Recent News

• 08.20.2025 - 4 - Statement of changes in beneficial ownership of securities
• 08.08.2025 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 07.31.2025 - Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit
• 07.29.2025 - SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors
• 07.16.2025 - SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors
• 06.23.2025 - Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
• 05.09.2025 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 05.09.2025 - 8-K - Current report
• 05.06.2025 - Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
• 04.28.2025 - Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Recent Filings

• 08.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.29.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.16.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.09.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.09.2025 - 8-K Current report